Apr 10, 2023 | News
On April 12, 2023, Denovicon Therapeutics Founder & CEO, Scott Bembenek, will present on ‘Enhanced Active Learning by Combining Machine Learning and Structure-Based Methods’ at the Drug Discovery Chemistry Conference: Artificial Intelligence for Early Drug...
Oct 18, 2022 | News
On October 11, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek, presented on ‘An AI–Molecular Modeling Platform for Streamlining Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2022.
Feb 4, 2022 | News
On February 8, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek talked (along with BIOVIA’s Guy Oshiro) at SLAS 2022 about how AI and the use of virtual–real cycles is revolutionizing the drug discovery process.
Jan 12, 2022 | News
Denovicon was pleased to participate in BIO Partnering at JPM 2022. If you’re interested in learning more about our AI/machine learning/molecular modeling platform and current molecular assets, feel free to reach out.
Sep 9, 2021 | News
On September 14, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, presented on Denovicon’s ‘AI–Molecular Modeling Platform for Enhanced Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2021.
Mar 13, 2021 | News
On March 15, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, talked on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in Small-Molecule Drug Design’ at the AI in Drug Discovery 2021.
Nov 14, 2020 | News
On November 16, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, spoke at the Global Pharma R&D AI, Data Science and Informatics Summit (PRADI 2020) on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in...
Oct 8, 2020 | News
On November 5, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, took part in the Lab of the Future panel entitled ‘Strategies for Accelerating Drug Discovery with AI.’
Jul 15, 2020 | News
On July 14, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, shared some of his experiences and insights from his scientific and entrepreneurial journeys (thus far) with Rady and UCSD students at Rady’s Careers in Biotech Panel.
Jun 26, 2020 | News
As part of Denovicon Therapeutics’ commitment to COVID-19, we tasked our novel molecular modeling-artificial intelligence (AI) hybrid computational platform to find potential therapies from over 13,000 FDA-approved drugs and clinical candidates. The molecular modeling...
